---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-084468"
form_type: "8-K"
ticker: "LQDA"
cik: "0001819576"
company_name: "Liquidia Corp"
filed_at: "2023-07-27T23:59:59+00:00"
generated_at: "2026-06-13T00:50:02.052821+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Liquidia submits NDA amendment to add PH-ILD indication for YUTREPIA; no new clinical data

## Summary
- Submitted amendment to add PH-ILD indication to tentatively approved NDA for YUTREPIA; no new clinical data needed.
- Final approval of PH-ILD indication possible after Tyvaso exclusivity expires March 31, 2024.
- Recertified paragraph IV that YUTREPIA does not infringe Tyvaso patents; all prior patent challenges won.
- Preparing for potential YUTREPIA launch between end of 2023 and mid-2024.
- Third Amendment to HCR financing: $10M second tranche received; future tranches require mutual agreement.

## SEC filing metadata
- accession: 0001104659-23-084468
- form_type: 8-K
- ticker: LQDA
- cik: 0001819576
- company_name: Liquidia Corp
- filed_at: 2023-07-27T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819576/000110465923084468/0001104659-23-084468-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819576/000110465923084468/tm2322220d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-084468
- JSON: https://secwatch.observer/filing/0001104659-23-084468.json
- Plain text: https://secwatch.observer/filing/0001104659-23-084468.txt

## Key facts
- Material Agreements
  Liquidia Corp amended Third Amendment to the Financing Agreement with HealthCare Royalty Partners IV, L.P. and HealthCare Royalty Management, LLC (collectively, “HCR”) valued at $10 million second tranche (effective 2023-07-27).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: HealthCare Royalty Partners IV, L.P. and HealthCare Royalty Management, LLC (collectively, “HCR”)
  - Value: $10 million second tranche
  - Effective: 2023-07-27
  source text: On July 27, 2023, Liquidia Technologies and HCR entered into a Third Amendment to the Financing Agreement (the “Third Amendment”), pursuant to which, among other things, (i) HCR agreed to make payment of the $10 million second tranche under the Financing Agreement on July 27, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819576/000110465923084468/0001104659-23-084468-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.